Skip to content
2000
Volume 23, Issue 4
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Background: The preferred approach for the treatment of neovascular age-related macular degeneration (AMD) is frequent intravitreal injections of the anti-vascular endothelial growth factor (VEGF) agents. However, considering the limitations of current anti-VEGF approaches, including the need for frequent injections, inadequate response in some patients, and a relatively short duration of effect, several new therapeutic modalities are under evaluation. Methods: A comprehensive review of the literature was performed on the new treatment modalities for neovascular AMD, and the relevant studies were discussed. Results: The treatment modalities for neovascular AMD include new anti-VEGF drugs, new drug delivery systems and new targets in the pathogenic cascade of choroidal neovascularization. These new modalities are in different phases of clinical development. Conclusion: The results of the completed studies reporting the new therapeutic modalities for neovascular AMD thus far are promising.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612822666161216121105
2017-02-01
2025-05-10
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612822666161216121105
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test